Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer

NCT02595879 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02595879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02595879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 18, 2019
Completion date
April 29, 2027
Enrollment
21 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cervical adenocarcinoma, advanced cervical adenosquamous carcinoma, advanced cervical squamous cell carcinoma, advanced vaginal adenocarcinoma, advanced vaginal adenosquamous carcinoma, advanced vaginal squamous cell carcinoma, stage ib2 cervical cancer ajcc v6 and v7, stage ii cervical cancer ajcc v7, stage ii vaginal cancer ajcc v6 and v7, stage iii vaginal cancer ajcc v6 and v7, stage iiib cervical cancer ajcc v6 and v7, stage iva cervical cancer ajcc v6 and v7, stage iva vaginal cancer ajcc v6 and v7